carnitine has been researched along with Adverse Drug Event in 11 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a prospective study to evaluate the ability of L-carnitine, which is involved in the β-oxidation of fatty acids, to reduce muscle cramps in patients with cirrhosis." | 7.81 | L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. ( Asano, Y; Gondo, K; Hattori, N; Hosokawa, T; Itakura, J; Izumi, N; Kurosaki, M; Matsuda, S; Nakakuki, N; Nakanishi, H; Suzuki, S; Takada, H; Takahashi, Y; Tamaki, N; Tsuchiya, K; Yasui, Y, 2015) |
| "Valproic acid (VPA) is a short-chain fatty acid widely prescribed in the treatment of seizure disorders and epilepsy syndromes, although its therapeutic value may be undermined by its toxicity." | 5.91 | Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation. ( Fagiolino, P; Ibarra, M; Maldonado, C; Schiavo, A; Trocóniz, IF; Vázquez, M, 2023) |
| "We performed a prospective study to evaluate the ability of L-carnitine, which is involved in the β-oxidation of fatty acids, to reduce muscle cramps in patients with cirrhosis." | 3.81 | L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. ( Asano, Y; Gondo, K; Hattori, N; Hosokawa, T; Itakura, J; Izumi, N; Kurosaki, M; Matsuda, S; Nakakuki, N; Nakanishi, H; Suzuki, S; Takada, H; Takahashi, Y; Tamaki, N; Tsuchiya, K; Yasui, Y, 2015) |
| " More rigorous studies are needed relative to the long-term use of these supplements in homogenous populations with standardized measurements of cognition." | 3.01 | Over the Counter Supplements for Memory: A Review of Available Evidence. ( Grossberg, G; He, S; Hersant, H; Maliha, P, 2023) |
| "Drug-induced liver injury (DILI) is a rare but serious adverse event that can progress to acute liver failure (ALF)." | 2.82 | Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review. ( Aithal, GP; Alvarez-Alvarez, I; Andrade, RJ; Arikan, C; Atallah, E; Lucena, MI; Medina-Caliz, I; Niu, H, 2022) |
| "Valproic acid (VPA) has demonstrated potential as a therapeutic candidate for spinal muscular atrophy (SMA) in vitro and in vivo." | 2.75 | SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy. ( Acsadi, G; Bromberg, MB; Chan, GM; Crawford, TO; D'Anjou, G; Elsheik, B; Kissel, JT; Krosschell, KJ; LaSalle, B; Maczulski, JA; Prior, TW; Reyna, SP; Schroth, MK; Scott, CB; Simard, LR; Sorenson, SL; Swoboda, KJ, 2010) |
| "Valproic acid (VPA) is a short-chain fatty acid widely prescribed in the treatment of seizure disorders and epilepsy syndromes, although its therapeutic value may be undermined by its toxicity." | 1.91 | Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation. ( Fagiolino, P; Ibarra, M; Maldonado, C; Schiavo, A; Trocóniz, IF; Vázquez, M, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 3 (27.27) | 2.80 |
| Authors | Studies |
|---|---|
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Niu, H | 1 |
| Atallah, E | 1 |
| Alvarez-Alvarez, I | 1 |
| Medina-Caliz, I | 1 |
| Aithal, GP | 1 |
| Arikan, C | 1 |
| Andrade, RJ | 1 |
| Lucena, MI | 1 |
| Schiavo, A | 1 |
| Maldonado, C | 1 |
| Vázquez, M | 1 |
| Fagiolino, P | 1 |
| Trocóniz, IF | 1 |
| Ibarra, M | 1 |
| Hersant, H | 1 |
| He, S | 1 |
| Maliha, P | 1 |
| Grossberg, G | 1 |
| Nakanishi, H | 1 |
| Kurosaki, M | 1 |
| Tsuchiya, K | 1 |
| Nakakuki, N | 1 |
| Takada, H | 1 |
| Matsuda, S | 1 |
| Gondo, K | 1 |
| Asano, Y | 1 |
| Hattori, N | 1 |
| Tamaki, N | 1 |
| Suzuki, S | 1 |
| Yasui, Y | 1 |
| Hosokawa, T | 1 |
| Itakura, J | 1 |
| Takahashi, Y | 1 |
| Izumi, N | 1 |
| Karaa, A | 1 |
| Kriger, J | 1 |
| Grier, J | 1 |
| Holbert, A | 1 |
| Thompson, JL | 1 |
| Parikh, S | 1 |
| Hirano, M | 1 |
| Swoboda, KJ | 1 |
| Scott, CB | 1 |
| Crawford, TO | 1 |
| Simard, LR | 1 |
| Reyna, SP | 1 |
| Krosschell, KJ | 1 |
| Acsadi, G | 1 |
| Elsheik, B | 1 |
| Schroth, MK | 1 |
| D'Anjou, G | 1 |
| LaSalle, B | 1 |
| Prior, TW | 1 |
| Sorenson, SL | 1 |
| Maczulski, JA | 1 |
| Bromberg, MB | 1 |
| Chan, GM | 1 |
| Kissel, JT | 1 |
| Prohaska, ES | 1 |
| Muzyk, AJ | 1 |
| Rivelli, SK | 1 |
| Kanai, Y | 1 |
| Sengers, RC | 1 |
| Stadhouders, AM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multi-center Phase II Trial of Valproic Acid and Carnitine in Patients With Spinal Muscular Atrophy (SMA CARNI-VAL Trial)[NCT00227266] | Phase 2 | 94 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 2.28 | 2.32 |
| Cohort 1b Sitters Treatment | 2.93 | 2.37 |
| Cohort 2 Standers and Walkers - Treatment | 5.52 | 6.56 |
The maximum Compound Motor Action Potential (CMAP) is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This is done multiple times, the outcome used is the highest peak, or response observed. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mV (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 1.91 | 1.44 |
| Cohort 1b Sitters Treatment | 2.2 | 1.8 |
| Cohort 2 Standers and Walkers - Treatment | 5.3 | 5.85 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Mean) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 5.46 | 5.28 |
| Cohort 1b Sitters Treatment | 5.45 | 5.26 |
| Cohort 2 Standers and Walkers - Treatment | 14.85 | 16.26 |
The maximum Compound Motor Action Potential (CMAP) area is a measurement obtained through EMG testing that is associated with disease progression. In this study, we measure the maximum CMAP by stimulating one nerve in the hand and measuring the response of the muscle. This procedure is repeated multiple times. The maximum area is the response that results in the largest area under the response curve. (NCT00227266)
Timeframe: 1 month prior to official enrollment, beginning of study (0 months), 6 months, 12 months (data point not available)
| Intervention | mVms (Median) | |
|---|---|---|
| Baseline | 6 months | |
| Cohort 1a Sitters Placebo Then Treatment | 3.6 | 3.74 |
| Cohort 1b Sitters Treatment | 4.6 | 3.4 |
| Cohort 2 Standers and Walkers - Treatment | 13.65 | 16.85 |
Comparison of Modified Hammersmith Change from baseline to 6 months. Scores range from 0 to 40. A higher score indicates a better outcome. This scale is used to assess gross motor abilities of non-ambulant children with SMA in multiple research trials as well as in clinical settings. (NCT00227266)
Timeframe: 0 months, 6 months
| Intervention | Score (Mean) | ||
|---|---|---|---|
| Baseline visit (0 weeks) | 6 Month visit (V2) | Change from Baseline | |
| Cohort 1a Sitters Placebo Then Treatment | 20.0 | 20.6 | 0.6 |
| Cohort 1b Sitters Treatment | 16.6 | 16.8 | 0.2 |
"Baseline Modified Hammersmith Extend testing. The baseline test is the score they receive during their screening visits. This scale ranges from 0 to 56. A higher score indicates a better outcome.~This scale is used to assess gross motor abilities of children with SMA in multiple research trials as well as in clinical settings." (NCT00227266)
Timeframe: 1 month prior to enrollment, at enrollment (0 months)
| Intervention | Score (Mean) | |
|---|---|---|
| Modified Hammersmith Extend at S1 (-4 weeks) | Modified Hammersmith Extend at S2 (0 weeks) | |
| Cohort 2 Experimental | 47.0 | 48.3 |
4 reviews available for carnitine and Adverse Drug Event
| Article | Year |
|---|---|
Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review.
Topics: Acetaminophen; Acetylcysteine; Adolescent; Adrenal Cortex Hormones; Adult; Carnitine; Chemical and D | 2022 |
Over the Counter Supplements for Memory: A Review of Available Evidence.
Topics: Aged; Brain; Carnitine; Choline; Dietary Supplements; Drug-Related Side Effects and Adverse Reaction | 2023 |
[Molecular mechanism in biological transport in the kidney: Organic cation/anion transporters].
Topics: Animals; Biological Transport; Carnitine; Carrier Proteins; Drug-Related Side Effects and Adverse Re | 2006 |
Secondary mitochondrial pathology.
Topics: Carnitine; Cytochrome-c Oxidase Deficiency; Drug-Related Side Effects and Adverse Reactions; Humans; | 1987 |
1 trial available for carnitine and Adverse Drug Event
| Article | Year |
|---|---|
SMA CARNI-VAL trial part I: double-blind, randomized, placebo-controlled trial of L-carnitine and valproic acid in spinal muscular atrophy.
Topics: Age Factors; Body Composition; Body Mass Index; Body Weight; Bone Density; Carnitine; Child; Child, | 2010 |
6 other studies available for carnitine and Adverse Drug Event
| Article | Year |
|---|---|
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Quantitative systems pharmacology Model to characterize valproic acid-induced hyperammonemia and the effect of L-carnitine supplementation.
Topics: Ammonia; Anticonvulsants; Carnitine; Dietary Supplements; Drug Overdose; Drug-Related Side Effects a | 2023 |
L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis.
Topics: Carnitine; Drug-Related Side Effects and Adverse Reactions; Humans; Liver Cirrhosis; Muscle Cramp; P | 2015 |
Mitochondrial disease patients' perception of dietary supplements' use.
Topics: Carnitine; Child; Dietary Supplements; Drug-Related Side Effects and Adverse Reactions; Female; Huma | 2016 |
Levocarnitine-induced hypophosphatemia in a hemodialysis patient with acute valproic acid toxicity.
Topics: Adolescent; Anticonvulsants; Bipolar Disorder; Carnitine; Drug-Related Side Effects and Adverse Reac | 2012 |